ABCB1 and osteosarcoma: This effect together with recent evidence that metformin may protect against doxorubicin-induced cardiotoxicity [57] and that it inhibits P-glycoprotein expression [58], one of the major adverse biomarkers in osteosarcoma [59] further supported its potential use as adjuvant drug.